Abstract
The commercial promise that a single, effective gene-therapy protocol carries has brought new companies into the race at an astounding rate. Whereas only a few years ago, gene therapy was regarded as too experimental to be worth major investment, there are now more than a dozen companies focusing solely on gene therapy, and many of the pharmaceutical giants are developing their own programmes, or collaborating by funding academic research. Nevertheless, although more than 40 protocols are now approved for trials, none have yet completed the rigorous regulatory, safety and efficacy «fitness testing» for widespread clinical use
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
